Value through Innovation27 July 2016

Clinical Study Results

  • FINALGON ® - Low Back Pain
    Clinical Study Number 69.52
    Study Indication Low Back Pain
    Product FINALGON ®
    Generic Name Nicoboxil + Nonivamide
    Lab Code
    Clinical Phase IIIb
    Study Title

    A multi-centre, double-blind, randomised, parallel group study to assess the efficacy and safety of multiple doses of topically applied hyperemisation-inducing ointment (2cm ointment line per application; up to 3 times daily for up to 4 days) containing 2.5% Nicoboxil/0.4% Nonivamide versus 2.5% Nicoboxil, 0.4% Nonivamide and placebo in patients 18 to 65 years of age with acute low back pain

    Study Document Trial synopsis 69.52_DR english
  • FINALGON ® - Low Back Pain
    Clinical Study Number 69.53
    Study Indication Low Back Pain
    Product FINALGON ®
    Generic Name Nicoboxil + Nonivamide
    Lab Code
    Clinical Phase III
    Study Title

    A multinational, randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of multiple doses of Finalgon® cream (1.08% Nicoboxil / 0.17% Nonivamide) in the treatment of acute low back pain

    Study Document Trial synopsis 69.53 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.